期刊文献+

应用PSA筛查前列腺癌的重要性及潜在危害 被引量:5

原文传递
导出
摘要 在美国,前列腺癌发病率已经超过肺癌,成为危害男性健康第一位的肿瘤。我国前列腺癌发病率低于欧美国家,但近年来呈明显的上升趋势,人们迫切需要寻求一种有效筛查前列腺癌的办法。白PSA检测应用于临床,
作者 杨进益
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2010年第4期286-287,共2页 Chinese Journal of Urology
  • 相关文献

参考文献18

  • 1李鸣,张思维,马建辉,陈万青,那彦群.中国部分市县前列腺癌发病趋势比较研究[J].中华泌尿外科杂志,2009,30(6):368-370. 被引量:171
  • 2徐勇,张志宏.我国前列腺癌诊治方面值得关注的几个问题[J].中华泌尿外科杂志,2009,30(6):365-367. 被引量:11
  • 3Schroder FH,Habbema DF,Roobol MJ,et al.Prostate cancer in the Swedish section of ERSPC-evidence for less metastases at diagnosis but not for mortality reduction.Eur Urol,2007,51:588-590.
  • 4叶敏.精益求精;进一步提高我国前列腺癌的诊治水平[J].中华泌尿外科杂志,2008,29:145-152.
  • 5Etzioni R,Gulati R,Falcon S,et al.Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States:a surveillance modeling approach.Med Decis Making,2008,28:323-331.
  • 6Lilja H,Ulmert D,Bjork T,et al.Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.J Clin Oncol,2007,25:431-436.
  • 7宋刚,周利群,那彦群.前列腺癌放射性粒子近距治疗[J].中华泌尿外科杂志,2007,28(4):285-287. 被引量:3
  • 8Korfage IJ,de Koning HJ.Habbema JD,et al.Side-effects of treatment for localized prostate cancer:are they valued differently by patients and healthy controls?BJU Int,2007,99:801-806.
  • 9Schroder FH.Biomarkers and screening for prostate cancer.Ann Oncol,2006,17:201-206.
  • 10Pelzer AE,Colleselli D,Bektic J,et al.Clinical and pathological features of screen vs non-screen-detected prostate cancers:is there a difference?BJU Int,2008,102:24-27.

二级参考文献54

共引文献177

同被引文献39

  • 1陈昭典.前列腺特异性抗原在前列腺癌早期诊断中的价值[J].临床外科杂志,2004,12(2):72-73. 被引量:8
  • 2侯惠如,杨丽.外科常见疾病老年健康教育手册[M].北京:人民军医出版社,2008:176-181.
  • 3李鸣.在我国推行前列腺癌规范化治疗的意义.临床泌尿外科杂志,2008,16:80-81.
  • 4Schroder FH,Hugosson J,Roobol MJ,et al.Prostate-cancermortality at 11 years of follow-up.N Engl J Med,2012,366:981-990.
  • 5Schroder FH,Hugosson J,Roobol MJ,et ai.Screening andprostate-cancer mortality in a randomized European study.N En-gl J Med,2009,360:1320-1328.
  • 6Gerald L,Andriole E,Crawford D,et al.Prostate cancerscreening in the randomized prostate,lung,colorectal,and o-varian cancer screening trial:mortality results after 13 years offollow-up natl.Cancer Inst,2012,104:125-132.
  • 7Dong F,Kattan MW,Steyerberg EW,et al.Validation of pre-treatment nomograms for predicting indolent prostate cancer:effi-cacy in contemporary urological practice.J Urol,2008,180:150-154.
  • 8Augustin H,Eggert T,Wenske S,et al.Comparison of accuracybetween the partin tables of 1997 and 2001 to predict final patho-logical stage in clinically localized prostate cancer.J Urol,2004,171:177-181.
  • 9Carroll PR.Nomograms are superior to staging and risk groupingsystems for indentifying high-risk patients:preoperative applica-tion in prostate cancer.Urol Oncol,2003,21:484-485.
  • 10李鸣,那彦群.不同水平前列腺特异抗原的前列腺癌诊断率[J].中华医学杂志,2008,88(1):16-18. 被引量:57

引证文献5

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部